Collegium Pharmaceutical
COLL
Halozyme Therapeutics
HALO
Precision Drilling
PDS
Hutchmed (China)
HCM
Enerpac Tool
EPAC
(Q1)Dec 31, 2024 | (FY)Sep 30, 2024 | (Q4)Sep 30, 2024 | (Q3)Jun 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 1,003.03%364M | -37.16%863.8M | -48.51%432.3M | -0.92%279.1M | -36.18%119.4M | -50.23%33M | 67.00%1.37B | 110.19%839.5M | -18.32%281.7M | 106.06%187.1M |
Net income from continuing operations | -16.43%178M | -25.88%947.3M | 15.80%238.2M | -42.04%231.1M | -10.14%265M | -43.75%213M | 39.05%1.28B | -38.78%205.7M | 35.24%398.7M | 496.96%294.9M |
Operating gains losses | 800.00%7M | -110.81%-10.8M | -588.89%-6.2M | -122.22%-2M | -101.46%-1.6M | 87.18%-1M | 326.92%99.9M | 94.23%-900K | 74.29%-900K | 322.78%109.5M |
Depreciation and amortization | 1.30%78M | 26.76%317.4M | 18.71%81.2M | 26.41%78.5M | 29.95%80.7M | 33.22%77M | 4.81%250.4M | 12.69%68.4M | 9.33%62.1M | -0.64%62.1M |
Deferred tax | ---- | 31.97%-68.1M | ---- | ---- | ---- | ---- | -197.92%-100.1M | ---- | ---- | ---- |
Change In working capital | 128.16%78M | -251.12%-421.7M | -66.02%161.6M | 50.39%-57.5M | -3.84%-248.8M | -15.32%-277M | 77.33%-120.1M | 1,298.82%475.6M | -345.77%-115.9M | -13.61%-239.6M |
-Change in receivables | -73.93%73M | 209.90%405.2M | 103.87%94.8M | 135.03%71.5M | 76.97%-41.1M | 958.90%280M | 11.28%-368.7M | 151.96%46.5M | -23.10%-204.1M | -116.10%-178.5M |
-Change in inventory | 196.43%27M | 144.44%131.5M | 352.14%63.3M | 111.20%10M | 290.29%86.2M | 84.03%-28M | -1.06%-295.9M | 116.17%14M | -27.94%-89.3M | 22.03%-45.3M |
-Change in payables and accrued expense | 87.50%-25M | -514.10%-290.7M | -98.76%1.8M | -8,133.33%-72.3M | 55.80%-20.2M | -571.14%-200M | -59.19%70.2M | 170.65%144.8M | -98.14%900K | -145.75%-45.7M |
-Change in other working capital | 100.91%3M | -240.78%-667.7M | -99.37%1.7M | -137.77%-66.7M | -1,015.38%-273.7M | -13,060.00%-329M | 6,979.10%474.3M | 72.61%270.3M | 9.49%176.6M | 117.58%29.9M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 1,003.03%364M | -37.16%863.8M | -48.51%432.3M | -0.92%279.1M | -36.18%119.4M | -50.23%33M | 67.00%1.37B | 110.19%839.5M | -18.32%281.7M | 106.06%187.1M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 89.84%-83M | -215.01%-982.5M | -108.16%-62.5M | -140.43%-43.7M | -4,841.67%-59.3M | -4,364.48%-817M | 11,052.56%854.3M | 737.75%765.7M | 137.58%108.1M | 98.75%-1.2M |
Capital expenditure reported | -4.41%-71M | -40.00%-224.7M | -2.69%-64.9M | 2.16%-40.7M | -62.22%-51.1M | -180.99%-68M | -13.75%-160.5M | -54.90%-63.2M | -127.32%-41.6M | 29.84%-31.5M |
Net business purchase and sale | --0 | -344.89%-749.2M | --0 | ---500K | 97.95%-700K | -459.04%-748M | -914.46%-168.4M | -300.00%-400K | --0 | -479.66%-34.2M |
Net investment purchase and sale | ---- | -100.83%-9.8M | -99.98%200K | -101.40%-2.1M | ---- | ---- | 686.77%1.18B | 527.01%833.3M | 135.11%150M | 223.21%55.2M |
Net other investing changes | -1,100.00%-12M | 1,300.00%1.2M | 155.00%2.2M | -33.33%-400K | -95.70%400K | 80.39%-1M | 80.00%-100K | -566.67%-4M | ---300K | --9.3M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 89.84%-83M | -215.01%-982.5M | -108.16%-62.5M | -140.43%-43.7M | -4,841.67%-59.3M | -4,364.48%-817M | 11,052.56%854.3M | 737.75%765.7M | 137.58%108.1M | 98.75%-1.2M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -289.55%-254M | 69.99%-502.8M | 67.32%-315.8M | 28.37%-295.6M | 86.72%-25.4M | 227.26%134M | -79.36%-1.68B | -112.07%-966.4M | -22.83%-412.7M | -111.27%-191.2M |
Net issuance payments of debt | -106.85%-28M | 176.98%674M | 93.94%-47.4M | 106.56%15.5M | 764.21%296.9M | 117.44%409M | -482.11%-875.5M | -223.12%-782.6M | -498.23%-236.3M | -238.39%-44.7M |
Net common stock issuance | 16.67%-100M | -90.98%-594.9M | -117.28%-118.2M | -163.33%-163M | -404.43%-193.7M | 23.47%-120M | -3.39%-311.5M | 34.30%-54.4M | 63.00%-61.9M | -2,642.86%-38.4M |
Cash dividends paid | -3.47%-149M | -5.27%-571M | -4.58%-141.7M | -4.80%-142M | -5.76%-143.3M | -5.96%-144M | -4.43%-542.4M | -5.04%-135.5M | -4.07%-135.5M | -4.15%-135.5M |
Proceeds from stock option exercised by employees | 154.55%28M | -55.48%39.4M | -46.56%7M | -78.65%5.7M | -55.52%15.7M | -17.91%11M | 52.85%88.5M | 11.02%13.1M | 551.22%26.7M | 246.08%35.3M |
Net other financing activities | 77.27%-5M | -44.96%-50.3M | -121.43%-15.5M | -107.02%-11.8M | 87.34%-1M | -56.03%-22M | -65.24%-34.7M | 48.15%-7M | -83.87%-5.7M | -426.67%-7.9M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -289.55%-254M | 69.99%-502.8M | 67.32%-315.8M | 28.37%-295.6M | 86.72%-25.4M | 227.26%134M | -79.36%-1.68B | -112.07%-966.4M | -22.83%-412.7M | -111.27%-191.2M |
Net cash flow | ||||||||||
Beginning cash position | -56.39%471M | 112.72%1.08B | -10.04%406.7M | 1.23%470.3M | -6.32%439M | 112.64%1.08B | -25.24%507.9M | -9.60%452.1M | 0.96%464.6M | -15.90%468.6M |
Current changes in cash | 104.15%27M | -212.33%-621.5M | -91.55%54M | -162.88%-60.2M | 754.72%34.7M | -1,034.38%-650M | 565.35%553.3M | 1,719.94%638.8M | -142.10%-22.9M | 94.46%-5.3M |
Effect of exchange rate changes | -400.00%-27M | -36.98%12.1M | 198.10%10.3M | -132.69%-3.4M | -392.31%-3.8M | -50.00%9M | 136.50%19.2M | 61.54%-10.5M | 171.72%10.4M | 200.00%1.3M |
End cash Position | 7.29%471M | -56.41%471M | -56.41%471M | -10.04%406.7M | 1.23%470.3M | -6.32%439M | 112.72%1.08B | 112.72%1.08B | -9.60%452.1M | 0.96%464.6M |
Free cash flow | 937.14%293M | -47.36%639.1M | -52.67%367.4M | -0.71%238.4M | -56.11%68.3M | -183.14%-35M | 78.02%1.21B | 116.48%776.3M | -26.48%240.1M | 239.00%155.6M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |